Sources

National cancer inequalities

Cancer burden

Cancer incidence

Incidence crude rate per 100,000 inhabitants
All cancers excl. non-melanoma skin cancer (C00-97/C44), both sexes, all ages
Globocan
Incidence age-standardized rate per 100,000 inhabitants
All cancers excl. non-melanoma skin cancer (C00-97/C44), both sexes, all ages
Globocan

Cancer mortality

Cancer mortality crude rate per 100,000 inhabitants
Global Cancer Observatory
Cancer mortality age-standardized rate per 100,000 inhabitants
Global Cancer Observatory
Breast cancer mortality
(Age-standardised) death rate per 100 000 inhabitants (men and women combined) due to breast cancer
Eurostat
Cervical cancer mortality
(Age-standardised) death rate per 100 000 women due to cervical cancer
Eurostat
Colorectal cancer mortality
5-year age-standardized net survival rate in colon cancer
Allemani, C., Matsuda, T., Di Carlo, V., Harewood, R., Matz, M., Nikšić, M., Bonaventure, A., Valkov, M., Johnson, C. J., Estève, J., Ogunbiyi, O. J., Azevedo E Silva, G., Chen, W. Q., Eser, S., Engholm, G., Stiller, C. A., Monnereau, A., Woods, R. R., Visser, O., Lim, G. H., … CONCORD Working Group (2018). Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet (London, England), 391(10125), 1023–1075. https://doi.org/10.1016/S0140-6736(17)33326-3
Stomach cancer mortality
5-year age-standardized net survival rate in rectum cancer
Allemani, C., Matsuda, T., Di Carlo, V., Harewood, R., Matz, M., Nikšić, M., Bonaventure, A., Valkov, M., Johnson, C. J., Estève, J., Ogunbiyi, O. J., Azevedo E Silva, G., Chen, W. Q., Eser, S., Engholm, G., Stiller, C. A., Monnereau, A., Woods, R. R., Visser, O., Lim, G. H., … CONCORD Working Group (2018). Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet (London, England), 391(10125), 1023–1075. https://doi.org/10.1016/S0140-6736(17)33326-3
Lung cancer mortality
Potential years of working life lost per 100,000 inhabitants aged 15-64 years, all cancers, both sexes
The Swedish Institute for Health Economics (IHE)
Potential years of working life lost
Potential years of working life lost per 100,000 inhabitants aged 15-64 years, all cancers, both sexes
The Swedish Institute for Health Economics (IHE)

Cancer survival

5-year survival rate in esophagus cancer
5-year age-standardized net survival rate in esophagus cancer
Allemani, C., Matsuda, T., Di Carlo, V., Harewood, R., Matz, M., Nikšić, M., Bonaventure, A., Valkov, M., Johnson, C. J., Estève, J., Ogunbiyi, O. J., Azevedo E Silva, G., Chen, W. Q., Eser, S., Engholm, G., Stiller, C. A., Monnereau, A., Woods, R. R., Visser, O., Lim, G. H., … CONCORD Working Group (2018). Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet (London, England), 391(10125), 1023–1075. https://doi.org/10.1016/S0140-6736(17)33326-3
5-year survival rate in stomach cancer
5-year age-standardized net survival rate in stomach cancer
Allemani, C., Matsuda, T., Di Carlo, V., Harewood, R., Matz, M., Nikšić, M., Bonaventure, A., Valkov, M., Johnson, C. J., Estève, J., Ogunbiyi, O. J., Azevedo E Silva, G., Chen, W. Q., Eser, S., Engholm, G., Stiller, C. A., Monnereau, A., Woods, R. R., Visser, O., Lim, G. H., … CONCORD Working Group (2018). Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet (London, England), 391(10125), 1023–1075. https://doi.org/10.1016/S0140-6736(17)33326-3
5-year survival rate in colon cancer
5-year age-standardized net survival rate in colon cancer
Allemani, C., Matsuda, T., Di Carlo, V., Harewood, R., Matz, M., Nikšić, M., Bonaventure, A., Valkov, M., Johnson, C. J., Estève, J., Ogunbiyi, O. J., Azevedo E Silva, G., Chen, W. Q., Eser, S., Engholm, G., Stiller, C. A., Monnereau, A., Woods, R. R., Visser, O., Lim, G. H., … CONCORD Working Group (2018). Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet (London, England), 391(10125), 1023–1075. https://doi.org/10.1016/S0140-6736(17)33326-3
5-year survival rate in rectum cancer
5-year age-standardized net survival rate in rectum cancer
Allemani, C., Matsuda, T., Di Carlo, V., Harewood, R., Matz, M., Nikšić, M., Bonaventure, A., Valkov, M., Johnson, C. J., Estève, J., Ogunbiyi, O. J., Azevedo E Silva, G., Chen, W. Q., Eser, S., Engholm, G., Stiller, C. A., Monnereau, A., Woods, R. R., Visser, O., Lim, G. H., … CONCORD Working Group (2018). Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet (London, England), 391(10125), 1023–1075. https://doi.org/10.1016/S0140-6736(17)33326-3
5-year survival rate in liver cancer
5-year age-standardized net survival rate in liver cancer
Allemani, C., Matsuda, T., Di Carlo, V., Harewood, R., Matz, M., Nikšić, M., Bonaventure, A., Valkov, M., Johnson, C. J., Estève, J., Ogunbiyi, O. J., Azevedo E Silva, G., Chen, W. Q., Eser, S., Engholm, G., Stiller, C. A., Monnereau, A., Woods, R. R., Visser, O., Lim, G. H., … CONCORD Working Group (2018). Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet (London, England), 391(10125), 1023–1075. https://doi.org/10.1016/S0140-6736(17)33326-3
5-year survival rate in pancreatic cancer
5-year age-standardized net survival rate in pancreatic cancer
Allemani, C., Matsuda, T., Di Carlo, V., Harewood, R., Matz, M., Nikšić, M., Bonaventure, A., Valkov, M., Johnson, C. J., Estève, J., Ogunbiyi, O. J., Azevedo E Silva, G., Chen, W. Q., Eser, S., Engholm, G., Stiller, C. A., Monnereau, A., Woods, R. R., Visser, O., Lim, G. H., … CONCORD Working Group (2018). Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet (London, England), 391(10125), 1023–1075. https://doi.org/10.1016/S0140-6736(17)33326-3
5-year survival rate in lung cancer
5-year age-standardized net survival rate in lung cancer
Allemani, C., Matsuda, T., Di Carlo, V., Harewood, R., Matz, M., Nikšić, M., Bonaventure, A., Valkov, M., Johnson, C. J., Estève, J., Ogunbiyi, O. J., Azevedo E Silva, G., Chen, W. Q., Eser, S., Engholm, G., Stiller, C. A., Monnereau, A., Woods, R. R., Visser, O., Lim, G. H., … CONCORD Working Group (2018). Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet (London, England), 391(10125), 1023–1075. https://doi.org/10.1016/S0140-6736(17)33326-3
5-year survival rate in melanoma
5-year age-standardized net survival rate in melanoma
Allemani, C., Matsuda, T., Di Carlo, V., Harewood, R., Matz, M., Nikšić, M., Bonaventure, A., Valkov, M., Johnson, C. J., Estève, J., Ogunbiyi, O. J., Azevedo E Silva, G., Chen, W. Q., Eser, S., Engholm, G., Stiller, C. A., Monnereau, A., Woods, R. R., Visser, O., Lim, G. H., … CONCORD Working Group (2018). Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet (London, England), 391(10125), 1023–1075. https://doi.org/10.1016/S0140-6736(17)33326-3
5-year survival rate in breast cancer
5-year age-standardized net survival rate in breast cancer
Allemani, C., Matsuda, T., Di Carlo, V., Harewood, R., Matz, M., Nikšić, M., Bonaventure, A., Valkov, M., Johnson, C. J., Estève, J., Ogunbiyi, O. J., Azevedo E Silva, G., Chen, W. Q., Eser, S., Engholm, G., Stiller, C. A., Monnereau, A., Woods, R. R., Visser, O., Lim, G. H., … CONCORD Working Group (2018). Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet (London, England), 391(10125), 1023–1075. https://doi.org/10.1016/S0140-6736(17)33326-3
5-year survival rate in cervical cancer
5-year age-standardized net survival rate in cervican cancer
Allemani, C., Matsuda, T., Di Carlo, V., Harewood, R., Matz, M., Nikšić, M., Bonaventure, A., Valkov, M., Johnson, C. J., Estève, J., Ogunbiyi, O. J., Azevedo E Silva, G., Chen, W. Q., Eser, S., Engholm, G., Stiller, C. A., Monnereau, A., Woods, R. R., Visser, O., Lim, G. H., … CONCORD Working Group (2018). Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet (London, England), 391(10125), 1023–1075. https://doi.org/10.1016/S0140-6736(17)33326-3
5-year survival rate in ovarian cancer
5-year age-standardized net survival rate in ovarian cancer
Allemani, C., Matsuda, T., Di Carlo, V., Harewood, R., Matz, M., Nikšić, M., Bonaventure, A., Valkov, M., Johnson, C. J., Estève, J., Ogunbiyi, O. J., Azevedo E Silva, G., Chen, W. Q., Eser, S., Engholm, G., Stiller, C. A., Monnereau, A., Woods, R. R., Visser, O., Lim, G. H., … CONCORD Working Group (2018). Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet (London, England), 391(10125), 1023–1075. https://doi.org/10.1016/S0140-6736(17)33326-3
5-year survival rate in prostate cancer
5-year age-standardized net survival rate in prostate cancer
Allemani, C., Matsuda, T., Di Carlo, V., Harewood, R., Matz, M., Nikšić, M., Bonaventure, A., Valkov, M., Johnson, C. J., Estève, J., Ogunbiyi, O. J., Azevedo E Silva, G., Chen, W. Q., Eser, S., Engholm, G., Stiller, C. A., Monnereau, A., Woods, R. R., Visser, O., Lim, G. H., … CONCORD Working Group (2018). Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet (London, England), 391(10125), 1023–1075. https://doi.org/10.1016/S0140-6736(17)33326-3
5-year survival rate in brain cancer
5-year age-standardized net survival rate in brain cancer
Allemani, C., Matsuda, T., Di Carlo, V., Harewood, R., Matz, M., Nikšić, M., Bonaventure, A., Valkov, M., Johnson, C. J., Estève, J., Ogunbiyi, O. J., Azevedo E Silva, G., Chen, W. Q., Eser, S., Engholm, G., Stiller, C. A., Monnereau, A., Woods, R. R., Visser, O., Lim, G. H., … CONCORD Working Group (2018). Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet (London, England), 391(10125), 1023–1075. https://doi.org/10.1016/S0140-6736(17)33326-3
5-year survival rate in myeloid cancers
5-year age-standardized net survival rate in myeloid cancers
Allemani, C., Matsuda, T., Di Carlo, V., Harewood, R., Matz, M., Nikšić, M., Bonaventure, A., Valkov, M., Johnson, C. J., Estève, J., Ogunbiyi, O. J., Azevedo E Silva, G., Chen, W. Q., Eser, S., Engholm, G., Stiller, C. A., Monnereau, A., Woods, R. R., Visser, O., Lim, G. H., … CONCORD Working Group (2018). Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet (London, England), 391(10125), 1023–1075. https://doi.org/10.1016/S0140-6736(17)33326-3
5-year survival rate in lymphoid cancers
5-year age-standardized net survival rate in lymphoid cancers
Allemani, C., Matsuda, T., Di Carlo, V., Harewood, R., Matz, M., Nikšić, M., Bonaventure, A., Valkov, M., Johnson, C. J., Estève, J., Ogunbiyi, O. J., Azevedo E Silva, G., Chen, W. Q., Eser, S., Engholm, G., Stiller, C. A., Monnereau, A., Woods, R. R., Visser, O., Lim, G. H., … CONCORD Working Group (2018). Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet (London, England), 391(10125), 1023–1075. https://doi.org/10.1016/S0140-6736(17)33326-3

Cancer prevention

Tobacco

Proportion of daily smokers of cigarettes
Proportion of self-reported daily smokers, aged 15+, both sexes
Eurostat
Relative price level of tobacco
Price level indices for "Tobacco"
Eurostat

Alcohol

Alcohol consumption (quantity)
Total per capita consumption in litres of pure alcohol, aged 15+
World Health Organization (WHO)
Alcohol consumption (frequency)
Proportion of people consuming alcohol at least every month (including those that reported to drink daily, weekly or monthly in the 12 months preceding data collection), aged 15+, both sexes
Eurostat
Relative price level of alcohol
Price level indices for alcoholic beverages
Eurostat

Obesity

Obesity rate
Proportion of people with a Body Mass Index (BMI) ≥ 30
Eurostat
Overweight rate
Proportion of people with a Body Mass Index (BMI) ≥ 25
Eurostat

Nutrition and physical activity

Fruit & vegetables consumption
Proportion of people consuming 5 or more portions of fruit and vegetables a day
Eurostat
Physical inactivity rate
Rate of people performing physical activity outside working time for more than 180 minutes per week, aged 16+
Eurostat

HPV

Status of HPV national immunisation program introduced (boys/girls/both)
European Centre for Disease Prevention and Control (ECDC)

Other infections

HepC infection rate
Estimated hepatitis C viraemic prevalence
CDA Foundation (CDAF)
HepC elimination status
Status of the Relative or Absolute Impact and Programmatic Targets by 2030
CDA Foundation (CDAF)

Other environmental and occupational factors

PM 2.5
Annual mean concentration of particulate matter 2.5 (PM2.5) at urban background stations in agglomerations
Eurostat
PM 10
Annual mean concentration of particulate matter 10 (PM10) at urban background stations in agglomerations
Eurostat
HPV Awareness Ranking
Ranking position on EPF HPV Prevention Policy Atlas 2023
EPF HPV Prevention Policy Atlas 2023
Primary prevention / HPV Vaccination
Score on policy for primary prevention / HPV vaccination on the EPF HPV Prevention Policy Atlas 2023
EPF HPV Prevention Policy Atlas 2023
Secondary prevention / Cervical cancer screening
Score on secondary prevention / Cervical cancer screening on the HPV Prevention Policy Atlas 2023
EPF HPV Prevention Policy Atlas 2023
Availability of online information for HPV prevention
Score on availability of online information on the EPF HPV Prevention Policy Atlas 2023
EPF HPV Prevention Policy Atlas 2023
Eligibility for the vaccine (boys, girls, both)
Eligibility of vaccination
EPF HPV Prevention Policy Atlas 2023

Cancer screening and early detection

Breast cancer screening

Breast cancer screening rate
Self-reported last breast examination by X-ray among women in the last 2 years, aged 50-69
Eurostat
Women that reported to have never had breast examination by X-ray
Percentage of women aged 50-69 that reported to have never had breast examination by X-ray
Eurostat
Number of dedicated mammography machines (per 100 000 inhabitants)
Number of dedicated mammography machines (per 100 000 inhabitants) designed exclusively for taking mammograms
Eurostat

Cervical cancer screening

Cervical cancer screening rate
Self-reported last cervical smear test among women in the last 3 years, aged 20-69
Eurostat
Women who reported to have never had cervical smear test
Percentage of women aged 20 to 69 who reported to have never had cervical smear test, aged 20-69
Eurostat

Colorectal cancer screening

Colorectal cancer screening rate
Self-reported last colorectal cancer screening test by faecal occult blood test in the last 3 years, aged 50-74
Eurostat
People that reported to have never performed colorectal cancer screening
Percentage of people aged 50 to 74 that self-reported to have never performed colorectal cancer screening using faecal occult blood test
Eurostat
Secondary prevention / Cervical cancer screening
Score on secondary prevention / Cervical cancer screening
EPF HPV Prevention Policy Atlas 2023

Cancer diagnosis

Diagnostic imaging

CT scanners per 100,000 inhabitants
Eurostat
MRI units per 100,000 inhabitants
Eurostat
PET scanners per 100,000 inhabitants
Eurostat

Diagnosis examinations

People who reported to never had had colonoscopy
Percentage of population who reported to have never had colonoscopy
Eurostat

Diagnostic physicians

Pathologists per 100,000 inhabitants
Eurostat
Radiologists per 100,000 inhabitants
Eurostat

Biomarker testing

Availability of multi-biomarker testing
Availability of multi-biomarker test (NGS): high = >90%; medium = 75-90%; low = 75%, Proportion of labs offering any NGS modality in-house or through referral
European Federation of Pharmaceutical Industries and Associations (EFPIA)
Reimbursement of multi-biomarker testing
Reimbursement of multi-biomarker testing: high = >90%, medium = 75-90%, low = 75%, calculated based on the average proportion of tests reported to be covered by public reimbursement
European Federation of Pharmaceutical Industries and Associations (EFPIA)

Cancer treatment

Cancer medicines and medical oncology

Reimbursement status of new oncology medicines
Full public reimbursement in % of nedicines within oncology available to patients with central-marketing authorisation by the EMA between 2016 and 2019
European Federation of Pharmaceutical Industries and Associations (EFPIA)
Average reimbursement time of new oncology medicines
Reimbursement of medicines within oncology (as classified by IQVIA) with central-marketing authorisation by the EMA between 2016 and 2019, until 1st January 2021
European Federation of Pharmaceutical Industries and Associations (EFPIA)
Uptake of breast cancer medicines
Uptake of new cancer medicines, defined as standard weekly doses per number of cancer-specific deaths (per 100,000 inhabitants)
Hofmarcher, T., Lindgren, P., Wilking, N., & Jönsson, B. (2020). The cost of cancer in Europe 2018. European Journal of Cancer, 129, 41–49. https://doi.org/10.1016/j.ejca.2020.01.011
Uptake of colorectal cancer medicines
Uptake of new cancer medicines, defined as standard weekly doses per number of cancer-specific deaths (per 100,000 inhabitants)
Hofmarcher, T., Lindgren, P., Wilking, N., & Jönsson, B. (2020). The cost of cancer in Europe 2018. European Journal of Cancer, 129, 41–49. https://doi.org/10.1016/j.ejca.2020.01.011
Uptake of lung cancer medicines
Uptake of new cancer medicines, defined as standard weekly doses per number of cancer-specific deaths (per 100,000 inhabitants)
Hofmarcher, T., Lindgren, P., Wilking, N., & Jönsson, B. (2020). The cost of cancer in Europe 2018. European Journal of Cancer, 129, 41–49. https://doi.org/10.1016/j.ejca.2020.01.011
Uptake of prostate cancer medicines
Uptake of new cancer medicines, defined as standard weekly doses per number of cancer-specific deaths (per 100,000 inhabitants)
Hofmarcher, T., Lindgren, P., Wilking, N., & Jönsson, B. (2020). The cost of cancer in Europe 2018. European Journal of Cancer, 129, 41–49. https://doi.org/10.1016/j.ejca.2020.01.011
Uptake of melanoma medicines
Uptake of new cancer medicines, defined as standard weekly doses per number of cancer-specific deaths (per 100,000 inhabitants)
Hofmarcher, T., Lindgren, P., Wilking, N., & Jönsson, B. (2020). The cost of cancer in Europe 2018. European Journal of Cancer, 129, 41–49. https://doi.org/10.1016/j.ejca.2020.01.011
Uptake of multiple myeloma medicines
Uptake of new cancer medicines, defined as standard weekly doses per number of cancer-specific deaths (per 100,000 inhabitants)
Hofmarcher, T., Lindgren, P., Wilking, N., & Jönsson, B. (2020). The cost of cancer in Europe 2018. European Journal of Cancer, 129, 41–49. https://doi.org/10.1016/j.ejca.2020.01.011
Uptake of ovarian cancer medicines
Uptake of new cancer medicines, defined as standard weekly doses per number of cancer-specific deaths (per 100,000 inhabitants)
Hofmarcher, T., Lindgren, P., Wilking, N., & Jönsson, B. (2020). The cost of cancer in Europe 2018. European Journal of Cancer, 129, 41–49. https://doi.org/10.1016/j.ejca.2020.01.011
Uptake of immunotherapy medicines
Uptake of new cancer medicines, defined as standard weekly doses per number of cancer-specific deaths (per 100,000 inhabitants)
Hofmarcher, T., Lindgren, P., Wilking, N., & Jönsson, B. (2020). The cost of cancer in Europe 2018. European Journal of Cancer, 129, 41–49. https://doi.org/10.1016/j.ejca.2020.01.011

Radiation therapy

Radiation therapy machines per 1 million inhabitants
Number of radiation therapy machines per 1,000,000 inhabitants, used for "MV therapy" and "Brachytherapy"
Directory of Radiotherapy Centres (DIRAC)

Oncology nursing

Nurses per 100,000 inhabitants
Number of practising nurses per 100,000 inhabitants, non-cancer-specific
Eurostat

Treating physicians

Oncologists per 100,000 inhabitants
Eurostat
Hematologists per 100,000 inhabitants
Eurostat

Cancer care facilities

Comprehensive cancer centers per 1 million inhabitants
Number of ESMO Designated Centres of Integrated Oncology and Palliative Care per 1 million inhabitants
European Society for Medical Oncology (ESMO)/Eurostat

Cancer survivorship and quality of life

Supportive and palliative care

Palliative care services for adults per 100,000 inhabitants
Palliative care services for adults per 100,000 inhabitants, non-cancer specific
European Association for Palliative Care

Mental health and psycho-oncology

Psycho-oncology support mentioned in NCP
Extent of recognition and recommendations for psycho-oncology support in National Cancer Plans
Neamţiu, L., et al. (2016). Psycho-oncological support for breast cancer patients: A brief overview of breast cancer services certification schemes and national health policies in Europe. Breast (Edinburgh, Scotland), 29, 178–180. DOI: 10.1016/j.breast.2016.07.002
Psycho-oncology support with recommendation in NCP
Extent of recognition and recommendations for psycho-oncology support in National Cancer Plans
Neamţiu, L., et al. (2016). Psycho-oncological support for breast cancer patients: A brief overview of breast cancer services certification schemes and national health policies in Europe. Breast (Edinburgh, Scotland), 29, 178–180. DOI: 10.1016/j.breast.2016.07.003
Psycho-oncology support with recommendation and indicators in NCP
Extent of recognition and recommendations for psycho-oncology support in National Cancer Plans
Neamţiu, L., et al. (2016). Psycho-oncological support for breast cancer patients: A brief overview of breast cancer services certification schemes and national health policies in Europe. Breast (Edinburgh, Scotland), 29, 178–180. DOI: 10.1016/j.breast.2016.07.002

Right to be forgotten

Implementation status
Legal implementation of the "right to be forgotten" for cancer survivors
1. Scocca, G., & Meunier, F. (2020). A right to be forgotten for cancer survivors: A legal development expected to reflect the medical progress in the fight against cancer. Journal of Cancer Policy, 25, 100246. https://doi.org/10.1016/j.jcpo.2020.100246 2. European Cancer Organisation (ECO) 3. EuroCloud

Social inequalities

Age

Cancer burden

Colorectal cancer mortality by age
Age-standardised death rate per 100 000 inhabitants due to colorectal cancer by age
Eurostat
Stomach cancer mortality by age
Age-standardised death rate per 100 000 inhabitants due to stomach cancer by age
Eurostat
Lung cancer mortality by age
Age-standardised death rate per 100 000 inhabitants due to lung cancer by age
Eurostat

Cancer prevention

Proportion of daily smokers of cigarettes by age
Proportion of self-reported daily smokers, aged 15+, both sexes, by age
Eurostat
Alcohol consumption (frequency) by age
Proportion of people consuming alcohol at least every month, aged 15+, both sexes, by age
Eurostat
Obesity rate by age
Proportion of people with a Body Mass Index (BMI) ≥ 30 by age
Eurostat
Fruit & vegetables consumption by age
Proportion of people consuming 5 or more portions of fruit and vegetables a day by age
Eurostat
Physical inactivity by age
Rate of people that reported not to engage in health-enhancing aerobic physical activity (i.e. performing zero minutes of physical activity a week), aged 16+, by age
Eurostat

Cancer screening and early detection

Women that reported to have never had breast examination by X-ray by age
Percentage of women aged 50-69 that reported to have never had breast examination by X-ray by age
Eurostat
Women who reported to have never had cervical smear test by age
Percentage of women aged 20 to 69 who reported to have never had cervical smear by age
Eurostat
People that reported to have never performed colorectal cancer screening by age
Percentage of people aged 50 to 74 that self-reported to have never performed colorectal cancer screening using faecal occult blood test by age
Eurostat
People who reported to never had had colonoscopy by age
Percentage of population who reported to have never had colonoscopy by age
Eurostat

Education

Cancer prevention

Proportion of daily smokers of cigarettes per education level
Proportion of self-reported daily smokers, aged 15+, both sexes, per education level
Eurostat
Alcohol consumption (frequency) per education level
Proportion of people consuming alcohol at least every month, aged 15+, both sexes, by education level
Eurostat
Obesity rate per education level
Proportion of people with a Body Mass Index (BMI) ≥ 30, per education level
Eurostat
Fruit & vegetables consumption per education level
Proportion of people consuming 5 or more portions of fruit and vegetables a day, per education level
Eurostat
Physical inactivity per education level
Rate of people that reported not to engage in health-enhancing aerobic physical activity (i.e. performing zero minutes of physical activity a week), aged 16+, per education level
Eurostat

Cancer screening and early detection

Women that reported to have never had breast examination by X-ray per education level
Percentage of women aged 50-69 that reported to have never had breast examination by X-ray, per education level
Eurostat
Women who reported to have never had cervical smear test per education level
Percentage of women aged 20 to 69 who reported to have never had cervical smear per education level, aged 20-69, per education level
Eurostat
People that reported to have never performed colorectal cancer screening per education level
Percentage of people aged 50 to 74 that self-reported to have never performed colorectal cancer screening using faecal occult blood test, per education level
Eurostat

Cancer diagnosis

People who reported to never had had colonoscopy per education level
Percentage of population who reported to have never had colonoscopy, per education level
Eurostat

Income

Cancer prevention

Proportion of daily smokers of cigarettes per income
Proportion of self-reported daily smokers, aged 15+, both sexes, per income
Eurostat
Alcohol consumption (frequency) per income
Proportion of people consuming alcohol at least every month, aged 15+, both sexes, per income
Eurostat
Obesity rate per income
Proportion of people with a Body Mass Index (BMI) ≥ 30, per income
Eurostat
Fruit & vegetables consumption per income
Proportion of people consuming 5 or more portions of fruit and vegetables a day, per income
Eurostat
Physical inactivity per income
Rate of people that reported not to engage in health-enhancing aerobic physical activity (i.e. performing zero minutes of physical activity a week), aged 16, per income
Eurostat

Cancer screening and early detection

Women that reported to have never had breast examination by X-ray per income
Percentage of women aged 50-69 that reported to have never had breast examination by X-ray, per income
Eurostat
Women who reported to have never had cervical smear test per income
Percentage of women aged 20 to 69 who reported to have never had cervical smear, per income
Eurostat
People that reported to have never performed colorectal cancer screening per income
Percentage of people aged 50 to 74 that self-reported to have never performed colorectal cancer screening using faecal occult blood test, per education level
Eurostat

Cancer diagnosis

People who reported to never had had colonoscopy per income
Percentage of population who reported to have never had colonoscopy, per income
Eurostat

Gender

Cancer burden

Colorectal cancer mortality by gender
Age-standardised death rate per 100 000 inhabitants due to colorectal cancer
Eurostat
Stomach cancer mortality by gender
Eurostat
Lung cancer mortality by gender
Age-standardised death rate per 100 000 inhabitants due to lung cancer
Eurostat

Cancer prevention

Proportion of daily smokers of cigarettes by gender
Proportion of people smoking cigarettes daily (manufactured and hand-rolled)
Eurostat
Alcohol consumption (quantity) by gender
Total per capita consumption in litres of pure alcohol, aged 15+
World Health Organization (WHO)
Alcohol consumption (frequency) by gender
Proportion of people consuming alcohol at least every month, including those that reported to drink daily, weekly or monthly in the 12 months preceding data collection
Eurostat
Obesity rate by gender
Proportion of people with a Body Mass Index (BMI) ≥ 30
Eurostat
Fruit & vegetables consumption by gender
Proportion of people consuming 5 or more portions of fruit and vegetables a day
Eurostat
Physical inactivity by gender
Rate of people that reported not to engage in health-enhancing aerobic physical activity (i.e. performing zero minutes of physical activity a week), aged 16+, per education level
Eurostat
HPV vaccination coverage by gender
HPV Vaccination coverage, complete schedule, aged 15+, both sexes
World Health Organization (WHO)

Cancer screening and early detection

People that reported to have never performed colorectal cancer screening by gender
Percentage of people aged 50 to 74 that self-reported to have never performed colorectal cancer screening using faecal occult blood test
Eurostat

Cancer diagnosis

People who reported to never had had colonoscopy by gender
Percentage of population who reported to have never undergone colonoscopy
Eurostat

Rural/urban differences

Cancer prevention

Proportion of daily smokers of cigarettes per degree of urbanisation
Proportion of self-reported daily smokers, aged 15+, both sexes, per degree of urbanisation
Eurostat
Alcohol consumption (frequency) per degree of urbanisation
Proportion of people consuming alcohol at least every month, aged 15+, both sexes, per degree of urbanisation
Eurostat
Obesity rate per degree of urbanisation
Proportion of people with a Body Mass Index (BMI) ≥ 30, per degree of urbanisation
Eurostat
Fruit & vegetables consumption per degree of urbanisation
Proportion of people consuming 5 or more portions of fruit and vegetables a day, per degree of urbanisation
Eurostat
Physical inactivity per degree of urbanisation
Rate of people that reported not to engage in health-enhancing aerobic physical activity (i.e. performing zero minutes of physical activity a week), aged 16+, per degree of urbanisation
Eurostat

Cancer screening and early detection

Women that reported to have never had breast examination by X-ray per degree of urbanisation
Percentage of women aged 50-69 that reported to have never had breast examination by X-ray, per degree of urbanisation
Eurostat
Women who reported to have never had cervical smear test per degree of urbanisation
Percentage of women aged 50-69 that reported to have never had breast examination by X-ray, per degree of urbanisation
Eurostat
People that reported to have never performed colorectal cancer screening per degree of urbanisation
Percentage of people aged 50 to 74 that self-reported to have never performed colorectal cancer screening using faecal occult blood test, per degree of urbanisation
Eurostat

Cancer diagnosis

People who reported to never had had colonoscopy per degree of urbanisation
Percentage of population who reported to have never had colonoscopy, per degree of urbanisation
Eurostat